Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) is granted a new patent in Australia protecting its in-house R327 and R529 anti-infectives
- Recce is primarily focused on R327 which is the subject of an ongoing trial showing superior results so far compared to competitor products
- R327 is being used to treat UTIs and trial patients have shown high bacterial elimination rates in urine after being injected with up to 2500mg
- RCE CEO James Graham suggests the patent affords the company a desirable market monopoly
- Recce shares last traded at 61 cents
Recce Pharmaceuticals (RCE) has been granted an Australian patent to protect the intellectual property (IP) rights of its disruptive synthetic anti-infectives.
The patent protects Recce’s flagship product, Recce 327 (R327), which is an intravenous serum that has been proven in ongoing trials to be superior at eliminating harmful bacteria from urine.
R327 is primarily marketed for treating urinary tract infections (UTIs). RCE’s other product, Recce 529 (R529), is also now recognised under patent law in the country.
While UTIs are the current focus of the ongoing trial alongside NSW-based partner Scientia, Recce highlighted its products also stand ready for penetration of the burn wounds market, as well as that for gonorrhoea and influenza.
The Australian Patent Office’s (APO) latest anti-infective patent to Recce is titled “Process for Preparation of Biologically Active Copolymer,” expiring in 2041.
The patent protects the process for preparation of the anti-infectives; the use of the treatments for disease, administration by all types of means, and also protects the company’s products as an aerosol, gel, foam or ointment. Transdermal delivery is also patented.
It also protects the treatment for use in a range of viral infections including but not limited to HIV, herpes, chicken pox, ross river virus, and COVID-19.
In short, no other company now has access to treating these conditions using the same type of drug that Recce is developing.
“We are thrilled to see this new family of intellectual property be granted in Australia,” Recce CEO James Graham said.
“With further market monopolies [we’re] reinforcing opportunities among a significant range of bacterial and viral pathogens.”
Recce shares last traded at 61 cents.
-1200x645-380x200.jpg)
